Healthcare Professionals
At Spark® Therapeutics, we are leveraging our unique technical and R&D expertise as we strive to bring gene therapies to patients. We are committed to working with the healthcare community as we expand our partnership to continue advancing state-of-the-art gene therapy research, education and support.
Visit the Spark Therapeutics website for U.S. healthcare professionals to access medical, scientific, and educational resources.
Access to genetic testing for IRDs
Inherited retinal diseases (IRDs, also known as inherited retinal dystrophies) are a group of rare blinding conditions caused by more than 270 different genes. It is estimated that more than two million people live with inherited retinal diseases (IRDs) globally, but only a small percentage of them have been genetically screened because of limited access to and information about genetic testing. In response to feedback from advocates, families affected by IRDs, and healthcare professionals about the current barriers preventing access to genetic screening for IRDs in a consistent manner, Spark Therapeutics has been working closely with physicians to help facilitate access to genetic screening for people with IRDs.
Learn more about genetic testing with these resources:
Eye Want 2 Know, Spark’s newest resource, aims to equip patients living with an IRD with the knowledge and resources they need to get started with genetic testing. Learn more about the benefits of genetic testing, locate a provider and connect with others in the community.
Visit Foundation Fighting Blindness for additional genetic testing resources.
References:
Berger W, Kloeckener-Gruissem B, Neidhardt J. The molecular basis of human retinal and vitreoretinal diseases. Prog Retin Eye Res. 2010;29(5):335-375.
Sahel J-A, Marazova K, Audo I. Clinical Characteristics and Current Therapies for Inherited Retinal Degenerations. Cold Spring Harb Perspect Med. 2014;5(2).
Veleri S, Lazar CH, Chang B, Sieving PA, Banin E, Swaroop A. Biology and therapy of inherited retinal degenerative disease: insights from mouse models. Dis Model Mech. 2015;8(2):109-129.
RetNet: Summaries of Genes and Loci Causing Retinal Diseases. RetNet. https://sph.uth.edu/retnet/sum-dis.htm. Updated January 10, 2023. Accessed March 3, 2023.
Maintaining an active dialogue with the scientific community
Spark Therapeutics seeks to actively engage with physicians, researchers and other healthcare professionals to better understand and provide education about diseases related to our therapeutic areas of interest.
The urgent needs of patients and the challenges before us demand uncompromising focus, tenacity and determination to create a fully integrated company built on world-class science, high-quality manufacturing and thoughtful, sustainable access. We embrace our ethical obligation to develop innovative, investigational treatments for life-altering and life-threatening genetic diseases as rapidly as possible without compromising product quality or patient safety.
To learn more, please click on one of the topics below.
Adverse Events in U.S.
and Product Complaints
To report an adverse event or a product complaint, click here and complete the submission form, or contact us by calling 1-855-SPARKTX/+1 855-772-7589.
Medical Questions
For HCPs in the US, go to www.SparkMedical.com. For HCPs outside the US, click here to complete our medical information request form or contact us by calling 1-855-SPARKTX (1-855-772-7589).
Our ongoing commitment to clinical research in hemophilia
Spark Therapeutics has clinical studies of investigational gene therapies for hemophilia A and an observational study, which is collecting real-time data about people living with hemophilia A.
Spark Therapeutics, Inc.
3737 Market Street
Philadelphia, PA 19104
Phone: 1-855-SPARKTX / +1 215-220-9300
N-SPK-US-700009-8
